ClinicalTrials.Veeva

Menu
H

Houston Metro Urology | Research Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Enzalutamide
Apalutamide
Prednisone
TAR-200
Niraparib
Abiraterone Acetate
Talazoparib
Gemcitabine
Androgen
Prednisone Versus Abiraterone Acetate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

19 of 33 total trials

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I\&T versus Hormone Therapy in Patients with Met...

Active, not recruiting
Metastasis From Malignant Tumor of Prostate
Drug: 177Lu-PSMA-I&T
Drug: Abiraterone with Prednisone or Enzalutamide

The aim of this study is to assess whether IW-3300 is safe and works for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). The m...

Active, not recruiting
Interstitial Cystitis
Bladder Pain Syndrome
Drug: Placebo
Drug: IW-3300 rectal foam

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist...

Active, not recruiting
Prostatic Neoplasms
Radiation: Radiotherapy
Drug: LHRHa

The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensi...

Enrolling
Metastatic Castrate-sensitive Prostate Cancer
Drug: Apalutamide
Drug: Androgen-deprivation Therapy (ADT)

The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib comb...

Active, not recruiting
Prostatic Neoplasms, Castration-Resistant
Drug: Niraparib 200 mg
Drug: Cetrelimab 480 mg

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus predniso...

Active, not recruiting
Metastatic Castration-sensitive Prostate Cancer
Drug: Niraparib
Drug: Prednisone

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP...

Active, not recruiting
Castration-Resistant Prostatic Cancer
Drug: Prednisone
Drug: New Formulation of Niraparib and Abiraterone Acetate (AA)

The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder canc...

Active, not recruiting
Non-muscle Invasive Bladder Cancer
Drug: Bacillus Calmette-Guerin
Drug: PF-06801591

The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.

Active, not recruiting
Urinary Bladder Neoplasms
Biological: Cetrelimab
Drug: TAR-200

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle inva...

Active, not recruiting
Bladder Cancer
Biological: Cetrelimab
Drug: TAR-200

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV)...

Active, not recruiting
Urinary Bladder Neoplasms
Drug: Cisplatin
Radiation: Hypo-fractioned radiation therapy

The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive b...

Enrolling
Non-Muscle Invasive Bladder Neoplasms
Drug: Mitomycin C
Drug: Gemcitabine

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's ch...

Enrolling
Non-Muscle Invasive Bladder Cancer
Drug: Gemcitabine
Drug: MMC

Prospective, randomized, double-blind, multicenter study to evaluate the safety and efficacy of an implantable tibial nerve stimulator in subjects wi...

Active, not recruiting
Lower Urinary Tract Symptoms
Urinary Bladder, Overactive
Device: INTIBIA Non-Therapeutic
Device: INTIBIA Therapeutic

This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients...

Enrolling
Superficial Bladder Cancer
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Drug: EG-70 (phase 2)
Drug: EG-70 (phase 1)

The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radica...

Active, not recruiting
Hormone Sensitive Prostate Cancer
Prostate Cancer
Drug: Enzalutamide
Drug: Leuprolide Open Label

This is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy. Up to appr...

Enrolling
High-grade Ta/ T1 Papillary Disease Bladder Cancer
Non Muscle Invasive Bladder Cancer
Biological: Cretostimogene Grenadenorepvec
Other: n-dodecyl-B-D-maltoside

The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination...

Active, not recruiting
Prostate Cancer
Drug: Placebo plus enzalutamide
Drug: talazoparib plus enzalutamide

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of tal...

Active, not recruiting
mCRPC
Drug: Talazoparib with enzalutamide
Drug: Placebo with enzalutamide

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Pfizer logo
Boston Scientific logo
A
Veru logo
Allergan logo
C
Coloplast logo
C
D

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems